Expert Interviews

A brief discussion on the role that JAK inhibitors play in cytopenic myelofibrosis and how best to optimize care with sequencing and dose adjustment.

In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.

Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.

The expert panel offers closing thoughts on MRD assessment and how ctDNA has been incorporated into clinical practice in the treatment of colorectal cancer.

In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.

Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.

Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.

Key safety data from the indirect comparison study of acalabrutinib versus zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Experts discuss recent data on a triplet combination therapy for patients with advanced non-clear cell renal cell carcinoma.

Drs Robert Motzer and Moshe Ornstein discuss the results of the KEYNOTE-B61 study in patients with non-clear cell renal cell carcinoma.

Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.

Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.

A brief discussion on optimal follow-up practices with patients on therapy for advanced bladder cancer.

Following a patient with bladder cancer who had a partial response to frontline therapy, panelists consider the branching treatment pathway.

While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.

Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.

A broader overview of the role that JAK inhibitors play in patients with myelofibrosis and how that role has continued to evolve in the current treatment paradigm.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses what strategies are being used to treat patients with bladder cancer during the chemotherapy shortage.

Moving on to review the first patient scenario of primary myelofibrosis, panelists elucidate the decisionmaking process when selecting JAK inhibitor therapy.

A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.